|
業務類別
|
Biotechnology |
|
業務概覽
|
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases. |
| 公司地址
| Gooimeer 2-35, Naarden, NH, NLD, 1411 DC |
| 電話號碼
| +31 352062971 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.newamsterdampharma.com |
| 員工數量
| 100 |
| Dr. Johannes Jacob Pieter Kastelein, F.E.S.C.,M.D.,PhD |
Chief Scientific Officer and Director |
美元 537.87K |
18/02/2026 |
| Mr. Ian Somaiya |
Chief Financial Officer |
美元 486.72K |
18/02/2026 |
| Dr. Michael Harvey Davidson, M.D. |
Chief Executive Officer and Director |
美元 646.15K |
18/02/2026 |
| Ms. Louise Kooij |
Chief Accounting Officer |
美元 452.22K |
18/02/2026 |
|
|
| Mr. Wouter Joustra |
Independent Director |
18/02/2026 |
| Mr. Mark C. McKenna |
Vice Chairman of the Board |
18/02/2026 |
| Dr. James N. Topper, M.D.,PhD |
Independent Director |
18/02/2026 |
| Dr. Johannes Jacob Pieter Kastelein, F.E.S.C.,M.D.,PhD |
Chief Scientific Officer and Director |
18/02/2026 |
| Ms. Adele M. Gulfo |
Independent Director |
18/02/2026 |
| Mr. John W. Smither |
Independent Director |
18/02/2026 |
| Dr. Michael Harvey Davidson, M.D. |
Chief Executive Officer and Director |
18/02/2026 |
| Mr. Louis G. Lange, M.D. |
Independent Director |
18/02/2026 |
| Ms. Janneke van der Kamp |
Independent Director |
18/02/2026 |
| Mr. William H. Lewis, J.D.,M.B.A. |
Chairman of the Board |
18/02/2026 |
|
|
|
|
